Mauricio Reinoso, MD
Pulmonary Disease · Sugar Land, TXNPI 1972597474
Payments from drug & device makers
Across 227 payments — averaging $97.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mylan Specialty L.p.$13K
- Sunovion Pharmaceuticals Inc.$4K
- Inspire Medical Systems, Inc.$1K
- AstraZeneca$733
- Veran Medical Technologies, Inc.$729
- Actelion Pharmaceuticals US, Inc.$391
- plus $2K from 28 others
What the payments were for
- Speaking & faculty fees$13,62962%
- Travel & lodging$3,55216%
- Food & beverage$4,60221%
- Education$3261%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mylan Specialty L.p. | 30 | $13,055 |
| Sunovion Pharmaceuticals Inc. | 20 | $3,814 |
| Inspire Medical Systems, Inc. | 14 | $1,346 |
| AstraZeneca | 40 | $733 |
| Veran Medical Technologies, Inc. | 5 | $729 |
| Actelion Pharmaceuticals US, Inc. | 19 | $391 |
| Jazz Pharmaceuticals Inc. | 6 | $374 |
| GSK | 18 | $253 |
| Philips North America LLC | 8 | $149 |
| Insmed, Inc. | 7 | $143 |
| Regeneron Healthcare Solutions, Inc. | 6 | $138 |
| Sanofi | 5 | $110 |
| Olympus America Inc. | 3 | $109 |
| Electromed, Inc. | 10 | $105 |
| Boehringer Ingelheim | 3 | $76 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $70 |
| Genentech USA, Inc. | 3 | $50 |
| Eisai Inc. | 2 | $43 |
| Circassia Inc. | 3 | $42 |
| United Therapeutics Corporation | 4 | $41 |
| Merck | 2 | $40 |
| Shionogi Inc | 2 | $36 |
| Gilead | 1 | $30 |
| Mallinckrodt Hospital Products Inc. | 2 | $29 |
| Optinose US, Inc. | 1 | $28 |
| Amgen | 1 | $25 |
| Johnson & Johnson | 1 | $24 |
| Grifols USA, LLC | 1 | $23 |
| Paratek Pharmaceuticals, Inc. | 1 | $22 |
| Harmony Biosciences LLC | 1 | $17 |
| Lilly USA, LLC | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Biogen | 1 | $16 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Yupelri$12,697
- LONHALA MAGNAIR$3,483
- Inspire$924
- Spin$690
- Inspire Upper Airway Stimulation System$228
How this compares
$22,108 in reported general payments places this provider in the 80th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 34 | $404,896 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 179 | $161,844 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $121,121 |
| Breo ElliptaFluticasone/Vilanterol | 158 | $79,509 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 117 | $71,880 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 60 | $48,120 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 45 | $41,568 |
| Spiriva HandihalerTiotropium Bromide | 17 | $11,900 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $11,720 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 19 | $10,946 |
| Doxepin Hcl | 112 | $7,385 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 25 | $6,438 |
| BreynaBudesonide/Formoterol Fumarate | 25 | $6,378 |
| Incruse ElliptaUmeclidinium Bromide | 14 | $4,873 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 154 | $4,859 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Combivent Respimat | $76 | $463,963113 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $253 | $318,105468 claims |
| Grifols USA, LLCProlastin C | $23 | $121,12112 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $733 | $53,28870 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Sugar Land
- Charles AndrewsSan Antonio$17M
- Ivan RosasHouston$13.8M
- Shahrukh KureishyMcKinney$12.4M
- Raksha JainDallas$3.4M
- Kelly ChinDallas$2.7M
- Julie PhilleyTyler$2.4M
- Nicola HananiaHouston$2.2M
- Sandeep SahayHouston$2.1M
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.